ProductNum | picture | CAS No. | Name and description | Formula | Quick order |
---|---|---|---|---|---|
CL2903B |
|
142373-60-2 |
Tirofiban hydrochloride | L700462 hydrochloride | MK383 hydrochloride) 98+% |
C22H37ClN2O5S | |
CL2903A |
|
144494-65-5 |
Tirofiban | L700462 | MK383 98+% |
C22H36N2O5S | |
CL2903 |
|
150915-40-5 |
Tirofiban Hydrochloride monohydrate | Tirofiban HCl | L700462 hydrochloride monohydrate | MK383 hydrochloride monohydrate 98+% |
C22H39ClN2O6S | |
CL2890 |
|
1228445-38-2 |
Pyrintegrin | PTN | N-(Cyclopropylmethyl)-4-((4-(6-hydroxy-3,4-dihydroquinolin-1(2H)-yl)pyrimidin-2-yl)amino)benzenesulfonamide 98+% |
C23H25N5O3S | |
CL2467 |
|
1025967-78-5 |
Lifitegrast; SAR 1118 98+% |
C29H24Cl2N2O7S | |
CLA1358 |
|
1342290-43-0 |
Abrilumab (Anti-Integrin a4b7 ITGA4 & ITGB7) 95+% |
— | |
CLA1352 |
|
1105038-73-0 |
Abituzumab (Anti-Integrin aV / ITGAV / CD51) 95+% |
— | |
CLA1265 |
|
1044758-60-2 |
Etrolizumab (Anti-Integrin α4β7) (ITGA4 & ITGB7) 95+% |
— | |
CLA1226 |
|
339086-79-2 |
Rovelizumab 95+% |
— | |
CLA1211 |
|
211323-03-4 |
Erlizumab (Synonyms: rhuMAb;Anti-Integrin b2 / ITGB2 / CD18) 95+% |
— | |
CLA1196 |
|
558480-40-3 |
Volociximab (Anti-Integrin a5b1 (ITGA5 & ITGB1)) 95+% |
— | |
CLA1185 |
|
892553-42-3 |
Etaracizumab 95+% |
— | |
CLA1118 |
|
143653-53-6 |
Abciximab 95+% |
— | |
CLA1108 |
|
159445-64-4 |
Odulimomab 95+% |
— | |
CLA1097 |
|
142864-19-5 |
Enlimomab 95+% |
— | |
CLA1084 |
|
339086-80-5 |
Tadocizumab 95+% |
— | |
CLA1062 |
|
214745-43-4 |
Anti-Human CD11a Monoclonal Antibody(Efalizumab) 95+% |
— | |
CLA1024 |
|
189261-10-7 |
Anti-Human CD49d Monoclonal Antibody(Natalizumab) 98+% |
— | |
CLA1011 |
|
943609-66-3 |
Vedolizumab 98+% |
— | |
CL1822 |
|
455264-30-9 |
Zaurategrast Ethyl Ester | CDP323 | UCB1184197 98+% |
C28H29BrN4O3 | |